Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 3
2008 4
2009 3
2010 2
2011 2
2013 2
2014 3
2015 3
2016 4
2017 5
2018 5
2019 1
2021 3
2022 2
2023 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
[A Case of Primary Schwannoma of the Urinary Bladder].
Matsumoto Y, Waku N, Kawai K, Ikeda A, Kimura T, Ishitsuka R, Kojima T, Suetomi T, Joraku A, Miyazaki J, Sakashita M, Nishiyama H. Matsumoto Y, et al. Among authors: joraku a. Hinyokika Kiyo. 2017 Aug;63(8):323-328. doi: 10.14989/ActaUrolJap_63_8_323. Hinyokika Kiyo. 2017. PMID: 28889717 Free article. Review. Japanese.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group. Shiota M, et al. Among authors: joraku a. Ann Surg Oncol. 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2. Epub 2024 Feb 14. Ann Surg Oncol. 2024. PMID: 38353798
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.
Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, Saito R, Morizane S, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Edamura K, Narita S, Yamaguchi T, Kasahara T, Hashimoto K, Kato M, Yoshino T, Akamatsu S, Matsukawa A, Kaneko T, Matsumoto R, Joraku A, Kato M, Saito T, Kato T, Tatarano S, Sakamoto S, Kanno H, Terada N, Nishiyama N, Kitamura H, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: joraku a. Int J Clin Oncol. 2024 Oct;29(10):1586-1593. doi: 10.1007/s10147-024-02580-6. Epub 2024 Jul 8. Int J Clin Oncol. 2024. PMID: 38976182
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer.
Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, Miyake H, Narita S, Miki J, Matsumoto R, Kato T, Saito T, Tomida R, Shiota M, Joraku A, Terada N, Suekane S, Kaneko T, Tatarano S, Yoshio Y, Yoshino T, Nishiyama N, Kawakami E, Ichikawa T, Kitamura H. Sakamoto S, et al. Among authors: joraku a. Sci Rep. 2024 Jul 3;14(1):15307. doi: 10.1038/s41598-024-65969-3. Sci Rep. 2024. PMID: 38961131 Free PMC article.
44 results